Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthma-A Romanian Perspective.

Camelia Elena Berghea Mihaela Bălgrădean Carmen Pavelescu Catalin Gabriel CirstoveanuClaudia Lucia TomaMarcela Daniela IonescuRoxana Silvia Bumbacea

Published in: Children (Basel, Switzerland) (2021)

This study showed that Omalizumab can be an effective and safe therapeutic option for Romanian children and adolescents with severe allergic asthma, providing clinically relevant information on asthma control and exacerbation rate in children and adolescents. The results demonstrated the positive effect of Omalizumab in young patients with asthma, starting from the first year of treatment.

Keyphrases

chronic obstructive pulmonary disease
allergic rhinitis
lung function
monoclonal antibody
early onset
cystic fibrosis
air pollution
middle aged